Initial approaches were candidate-based, such as the use of imatinib (Gleevec) for acute myeloid leukemias harboring BCR-ABL gene translocations, HER2Neu positive breast cancer treatment with trastuzumab (Herceptin), and, prior to this, tamoxifen in ER/PR positive breast cancer patients [5], [6]. Here, BCR is linked to breast carcinoma.